Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Genfit    GNFT   FR0004163111

GENFIT

(GNFT)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GENFIT : Half-Year Report of Liquidity Contract with CIC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 07:36am EDT

Lille - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announces the half-year report of its liquidity contract with CIC.

Under the liquidity contract granted to CIC by GENFIT, the following resources were in the liquidity account as at December 31, 2018: 27,911 shares

EUR 769,849.43 in cash

At the half-year report as at June 30, 2018, the following resources were available in the liquidity account: 8,693 shares - EUR215,618.25 in cash

ABOUT GENFIT

GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT's lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide ('RESOLVE-IT') in nonalcoholic steatohepatitis (NASH), considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive results in a Phase 2 clinical trial in Primary Biliary Cholangitis (PBC), a chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111).

GENFIT FORWARD LOOKING STATEMENT/DISCLAIMER

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, including its RESOLVE-IT Phase 3 trial, review and approvals by regulatory authorities, such as the FDA or the EMA, of its drug and diagnostic candidates, the success of any in-licensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed in Section 4 'Main Risks and Uncertainties' of the Company's 2017 Registration Document registered with the French Autorite des Marches Financiers on April 27, 2018 under n-degree R.18-032, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and as updated by the 2018 Half Year Business and Financial Report and available on the Investors page of GENFIT's website. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Contact:

Tel: +1 (617) 714 5252

Email: investors@genfit.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENFIT
03/15GENFIT : announces Launch of Proposed Global Offering and Nasdaq listing
AQ
03/15GLOBAL MARKETS LIVE : UBS, Facebook, BAT, Oracle…
03/14GENFIT : Announces Launch of Proposed Global Offering and Nasdaq Listing
GL
03/14GENFIT : Gets FDA Green Signal for Phase 2 Clinical Trial of Elafibranor
AQ
03/11GENFIT : Announces FDA Protocol Clearance for Phase 2 Clinical Trial of Elafibra..
GL
02/27GENFIT : Publication of the 2018 registration document
AQ
02/27GENFIT : Files registration statement for proposed initial public offering in th..
GL
02/05GENFIT : Reports Full-Year 2018 Financial Results, cash position of EUR207.2m as..
AQ
02/04GENFIT : Reports Full-Year 2018 Financial Results: cash position of €207.2m as ..
AQ
01/22GENFIT : announces its Financial Calendar for 2019
AQ
More news
Financials (€)
Sales 2019 30,5 M
EBIT 2019 -73,0 M
Net income 2019 -75,1 M
Finance 2019 92,7 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 70,43
EV / Sales 2019 20,6x
EV / Sales 2020 7,94x
Capitalization 720 M
Chart GENFIT
Duration : Period :
Genfit Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENFIT
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 68,8 €
Spread / Average Target 198%
EPS Revisions
Managers
NameTitle
Jean-François Mouney Chairman & Chief Executive Officer
Dean W. Hum Deputy CEO, Chief Operating & Scientific Officer
Nathalie Huitorel Chief Financial & Administrative Officer
Florence Séjourné Member-Supervisory Board
Xavier Guille des Buttes Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
GENFIT33.14%820
IQVIA HOLDINGS INC24.18%28 535
CELLTRION, INC.--.--%22 704
LONZA GROUP16.69%22 291
INCYTE CORPORATION36.94%18 639
SEATTLE GENETICS, INC.32.92%12 092